We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Activin a is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes.
- Authors
Chen, Weena J. Y.; Greulich, Sabrina; van der Meer, Rutger W.; Rijzewijk, Luuk J.; Lamb, Hildo J.; de Roos, Albert; Smit, Johannes W. A.; Romijn, Johannes A.; Ruige, Johannes B.; Lammertsma, Adriaan A.; Lubberink, Mark; Diamant, Michaela; Ouwens, D. Margriet
- Abstract
Background Activin A released from epicardial adipose tissue has been linked to contractile dysfunction and insulin resistance in cardiomyocytes. This study investigated the role of activin A in clinical diabetic cardiomyopathy by assessing whether circulating activin A levels associate with cardiometabolic parameters in men with uncomplicated type 2 diabetes (T2D), and the effects of treatment with pioglitazone versus metformin on these associations. Methods Seventy-eight men with uncomplicated T2D and fourteen healthy men with comparable age were included, in this randomized, double-blind, active comparator intervention study. All T2D men were on glimipiride monotherapy, and randomized to a 24-week intervention with either pioglitazone or metformin. Cardiac dimensions and -function were measured using magnetic resonance imaging, whilst myocardial glucose metabolism (MMRglu) was determined using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography during a hyperinsulinemic-euglycemic clamp. Results Circulating activin A levels were comparable in T2D men and controls. Activin A levels were independently inversely associated with MMRglu, and positively with left ventricular mass/volume (LVMV)-ratio in T2D men. Intervention with metformin decreased activin A levels, whereas pioglitazone did not alter activin A levels. The changes in plasma activin A levels were not correlated with the changes in MMRglu following either pioglitazone or metformin treatment. A borderline significant correlation (p = 0.051) of changes in plasma activin A levels and changes in LVMV-ratio was observed after pioglitazone treatment. Conclusions Circulating activin A levels are associated with impaired myocardial glucose metabolism and high LVMV-ratio in patients with uncomplicated T2D, reflecting a potential detrimental role in early human diabetic cardiomyopathy.
- Subjects
ACTIVIN; TRANSFORMING growth factors-beta; CARDIOMYOPATHIES; INSULIN resistance; PEOPLE with diabetes
- Publication
Cardiovascular Diabetology, 2013, Vol 12, Issue 1, p1
- ISSN
1475-2840
- Publication type
Article
- DOI
10.1186/1475-2840-12-150